Bringing High-Impact Medical Innovations to Life Through Risk-Reward Sharing Partnerships

Learn More

Orchestra BioMed™ is a Biomedical Innovation Company

Orchestra BioMed™ is a biomedical innovation company focused on developing high-impact therapeutic products to address significant unmet needs in procedure-based medicine.

Our partnership-enabled business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global strategics to optimize commercialization and profitability. Orchestra BioMed is led by an accomplished team of leaders with strong expertise in every phase of medtech and biopharma product development. Our primary goal is to rapidly advance transformative solutions that may have the potential to improve care for millions of patients worldwide.

Product Pipeline Overview

Advancing a multi-asset pipeline of high-impact therapeutic solutions.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies that target large unmet healthcare needs

BackBeat CNT™

Patented, intelligent bioelectronic treatment for hypertension

Virtue® SAB

First-in-class product to deliver sirolimus during angioplasty without the need for balloon coating or permanent implant

News & Events

Orchestra BioMed™ Appoints Drug-Device Combination Expert Jagdish Parasrampuria as Vice President of Pharmaceutical Development

July 13, 2020

New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Jagdish Parasrampuria M.Pharm., Ph.D., as Vice President of Pharmaceutical Development. Dr. Parasrampuria is an expert in small molecules, biologics, and drug-device combination products and will play a leadership role in the development of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB), a drug-device combination product for which the Company has a global strategic partnership with Terumo Corporation.

How Can Early-Stage Medical Device Companies Survive Market Turmoil?

May 23, 2020

Medical Device and Diagnostic Industry (MD+DI)

David Hochman, founder and CEO of Orchestra BioMed, shares how the company's risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic.

Click here for full article

Read All News